Compare · BMY vs SNY
BMY vs SNY
Side-by-side comparison of Bristol-Myers Squibb Company (BMY) and Sanofi (SNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BMY and SNY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- BMY is the larger of the two at $121.75B, about 1.1x SNY ($114.92B).
- BMY has been more active in the news (16 items in the past 4 weeks vs 12 for SNY).
- Both have 25 recent analyst ratings on file.
- Company
- Bristol-Myers Squibb Company
- Sanofi
- Price
- -
- -
- Market cap
- $121.75B
- $114.92B
- 1M return
- -
- +13.82%
- 1Y return
- -
- -4.88%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 16
- 12
- Recent ratings
- 25
- 25
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; DarwinHealth, Inc; and Bolt Biotherapeutics, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Latest BMY
- Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease
- Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat
- Bristol Myers Squibb Announces Evolution of Research & Development Organization
- Director Haller Julia A sold $240,578 worth of shares (3,800 units at $63.31), decreasing direct ownership by 11% to 30,279 units (SEC Form 4)
- Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions
- Leading Academic Medical Centers to Present New AI-ECG Research on Viz.ai’s Cardio Suite at AHA 2026
- EVP, Chief Commercial Officer Lenkowsky Adam converted options into 7,522 shares and covered exercise/tax liability with 3,848 shares, increasing direct ownership by 19% to 23,380 units (SEC Form 4)
- Chief Executive Officer Boerner Christopher S. converted options into 2,964 shares, acquired 406 shares and covered exercise/tax liability with 1,724 shares, increasing direct ownership by 8% to 23,097 units (SEC Form 4)
- EVP, Chief Supply Chain & Ops Shanahan Karin converted options into 6,281 shares and covered exercise/tax liability with 3,213 shares, increasing direct ownership by 12% to 28,956 units (SEC Form 4)
- EVP, Chief Digital & Tech Off. Meyers Gregory Scott converted options into 6,281 shares and covered exercise/tax liability with 2,665 shares, increasing direct ownership by 12% to 33,977 units (SEC Form 4)
Latest SNY
- Sanofi and the pan-Canadian Pharmaceutical Alliance sign Letter of Intent for Sarclisa®(isatuximab), a step toward public access for newly diagnosed, transplant-ineligible multiple myeloma patients
- FDA Approval for CHILDREN'S ALLEGRA HIVES issued to CHATTEM SANOFI
- FDA Approval for RIFADIN issued to SANOFI AVENTIS US
- FDA Approval for CHILDREN'S ALLEGRA ALLERGY issued to CHATTEM SANOFI
- FDA Approval for ALLEGRA ALLERGY issued to CHATTEM SANOFI
- FDA Approval for ALLEGRA HIVES issued to CHATTEM SANOFI
- FDA Approval for ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION issued to CHATTEM SANOFI
- Sanofi upgraded by BNP Paribas Exane
- SEC Form 13F-HR filed by Sanofi
- SEC Form 6-K filed by Sanofi